Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquired |
Crealta Pharmaceuticals
Raptor Pharmaceutical Corp. |
| gptkbp:ceo |
Timothy P. Walbert
|
| gptkbp:employees |
~500
|
| gptkbp:focus |
Rare diseases
|
| gptkbp:founded |
gptkb:2008
|
| gptkbp:headquarters |
gptkb:Lake_Forest,_Illinois
|
| https://www.w3.org/2000/01/rdf-schema#label |
Horizon Pharma USA, Inc.
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:products |
gptkb:Krystexxa
gptkb:Actimmune gptkb:Ravicti gptkb:Tepezza |
| gptkbp:revenue |
$1.1 billion (2020)
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.horizonpharma.com
|
| gptkbp:bfsParent |
gptkb:Horizon_Therapeutics
|
| gptkbp:bfsLayer |
5
|